What Researchers Did
This review explored the biological mechanisms, clinical efficacy, and existing controversies of hyperbaric oxygen therapy (HBOT) for sudden sensorineural hearing loss (SSNHL).
What They Found
Researchers found that hyperbaric oxygen therapy (HBOT) combined with glucocorticoids can significantly improve treatment outcomes for sudden sensorineural hearing loss (SSNHL), especially with early intervention. However, the optimal clinical application of HBOT remains undetermined due to a lack of standardized treatment parameters and inconsistent results from clinical studies.
What This Means for Canadian Patients
Canadian patients with sudden sensorineural hearing loss might benefit from hyperbaric oxygen therapy (HBOT) when combined with glucocorticoids, particularly if treatment is started early. However, the best way to use HBOT, including specific treatment settings and timing, is still being researched, so patients should discuss all options with their healthcare providers.
Canadian Relevance
This review does not have a direct Canadian connection.
Study Limitations
A key limitation is the lack of standardized treatment parameters for hyperbaric oxygen therapy and inconsistent results across existing clinical studies.